Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Tom DuBois who wrote (3228)	12/8/1997 9:07:00 PM
From: Peter Silsbee	Read Replies (1) \| Respond to of 6136

Tom: True, it was a mild pounce. My 7 month old orange cat is much scarier :) Concerning the downgrade: yes, it was announced, but neither the text nor a pointer had appeared on the thread, thus, I think it was a valuable contribution. Not as valuable as it would have been a week earlier, but still more valuable than, say, this piece I'm writing just now. Concerning "shooting the messenger," it happens constantly on SI, and there is at least one on this thread with a very itchy trigger finger. Normally I just stay out of the way, though it seens to have gotten more difficult lately. For some reason I felt like criticizing your post, something about straws and camel's backs I guess. Third, I am also skeptical of the motives of this new poster. But I am still glad that he posted the report. PLS [on topic (!)] --- Anyone really think there's a chance of anything happening with Thymitaq (i.e. outlicensing) for hepatoma?